Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4553 USD | -1.02% | -44.48% | +74.11% |
04-22 | GlucoTrack, Inc. announced that it has received $0.5 million in funding | CI |
04-16 | Glucotrack Expanding Glucose Monitoring Technology to Epidural Space | MT |
Sales 2022 | - | Sales 2023 | - | Capitalization | 5.46M 7.47M |
---|---|---|---|---|---|
Net income 2022 | -4M -5.47M | Net income 2023 | -7M -9.57M | EV / Sales 2022 | - |
Net cash position 2022 | 2.12M 2.89M | Net cash position 2023 | 4.3M 5.87M | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.92
x | P/E ratio 2023 |
-0.68
x | Employees | 6 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.25% |
1 day | -1.02% | ||
1 week | -44.48% | ||
Current month | +37.51% | ||
1 month | +38.10% | ||
3 months | +106.95% | ||
6 months | +133.49% | ||
Current year | +74.11% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Goode
CEO | Chief Executive Officer | 56 | 20-12-16 |
James Cardwell
DFI | Director of Finance/CFO | 64 | 23-10-10 |
David Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Drew Sycoff
BRD | Director/Board Member | 57 | 19-07-07 |
Luis J. Malavé
CHM | Chairman | 61 | 02-12 |
Director/Board Member | 95 | 09-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.4553 | -1.02% | 165,127 |
24-04-25 | 0.46 | -3.97% | 238,295 |
24-04-24 | 0.479 | -36.97% | 1,704,258 |
24-04-23 | 0.76 | -15.65% | 275,696 |
24-04-22 | 0.901 | +9.88% | 390,822 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+74.11% | 12.18M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- GCTK Stock